Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis - PubMed
a day ago
- #multiple sclerosis
- #ocrelizumab
- #paramagnetic rim lesions
- Paramagnetic rim lesions (PRLs) are chronic active MS lesions with iron-laden microglia/macrophages.
- Ocrelizumab, a CD20+ B cell-targeting monoclonal antibody, suppresses acute MS activity but its effect on PRLs was unclear.
- A study of 29 ocrelizumab-treated patients with PRLs showed higher baseline iron levels in PRLs compared to non-PRLs.
- After treatment, PRLs exhibited a significant reduction in iron content (QSM values), suggesting ocrelizumab may reduce iron-related inflammation in PRLs.